Response to Comments: MolDX: Gene Expression Profile Tests for Decision-Making in Castration Resistant and Metastatic Prostate Cancers

This document is a response-to-comments notice for the MolDX LCD concerning gene expression profile tests for castration-resistant and metastatic prostate cancer and does not itself state coverage indications, limitations, or frequency limits. It records the public comment period (08/31/2023–10/14/2023), the notice period start (08/08/2024), and the effective date (09/22/2024). For specific coverage criteria, consult the referenced LCD(s) (e.g., L39686/DL39636).

"This document is a response-to-comments notice and does not define coverage criteria; it records the public comment period (08/31/2023–10/14/2023), the notice period start (08/08/2024), and the eff..."

Sign up to see full coverage criteria, indications, and limitations.